A background therapy of the bronchial asthma is required to increase the vital amount of the lungs, reduce the attacks of bronchospasms and prevent COPD. In case of the severe types of the disease, patients are prescribed combined medications such as Symbicort.
Uses & Interactions
Symbicort is a combined medication to treat a bronchial asthma and contains Formoterol and Budesonide. These are ingredients with various mechanism of the action that have a similar therapeutic effect.
- Formoterol is beta-2-adrenergic receptors causing a relaxation of the smooth muscles of the bronchi
- Budesonide is a glucocorticosteroid medication with an intensive anti-inflammatory action.
Symbicort provides a pharmacological action during any types of the bronchial asthma and respiratory tract obstructions. A bronchodilatory action occurs quickly, within 2-3 minutes, and lasts for up to 12 hours due to Budesonide. That is why, this product may be used for a reduction of the bronchospasms, as well as background treatment of asthma.
Symbicort is indicated for the inhaler application, and a dose depends on a clinical picture of a patient.
- Adults and patients over 12 are prescribed Symbicort in the dose of 1-2 inhalations per day.
If bronchospasms grow, it is reasonable to increase the dose but not by means of increasing the inhalation frequency. The dose ration of Formoterol and Budesonide should be increased.
A standard dose of the active ingredients is 80 mcg Budesonide, and 4,5 mcg Formoterol. To increase a therapeutic effect, the dose should be increased up to 160 mcg Budesonide and 4,5 mcg Formoterol.
- Children under 12 are contraindicated to take Symbicort to treat the bronchial asthma.
- If tuberculosis of the lungs or infectious diseases in the lungs, the use of Symbicort is not recommended.
- As Symbicort provides some action on the functions of the cardiovascular system, patients with chronic pathologies of the heart should be careful.
Subscribe to our free newsletter